BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Empagliflozin/Linagliptin/Metformin

Lactic Acidosis

  • Postmarketing cases of metformin-associated lactic acidosis have resulted in death, hypothermia, hypotension, and resistant bradyarrhythmias. Symptoms included malaise, myalgias, respiratory distress, somnolence, and abdominal pain. Laboratory abnormalities included elevated blood lactate levels, anion gap acidosis, increased lactate/pyruvate ratio; and metformin plasma levels generally >5 mcg/mL.
  • Risk factors include renal impairment, concomitant use of certain drugs, age ?65 years old, radiological studies with contrast, surgery and other procedures, hypoxic states, excessive alcohol intake, and hepatic impairment. Steps to reduce the risk of and manage metformin-associated lactic acidosis in these high risk groups are provided in the Full Prescribing Information.
  • If lactic acidosis is suspected, discontinue TRIJARDY XR and institute general supportive measures in a hospital setting. Prompt hemodialysis is recommended.

FDA and Industry Communications

Information Index to FDA Safety Information

Patient Counseling Information

Medication Guides

Patient Medication Guide - TRIJARDY XR

Package Inserts

Empagliflozin/Linagliptin/Metformin

Updated June 2020